MaxCyte, Inc.
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from MaxCyte, Inc.'s yearly results (2022–2025), compared with Healthcare companies in United States. Tap ? on any ratio for what it means.
What stands out
- Steadiness Ratio: Sales and profit both fell in each of the last 3 years. Less steady than 96% of Healthcare companies in United States.
- Tangible Net Worth Ratio: Of every $100 of net worth, $100 is tangible; the rest is goodwill and other intangibles, often from buying other companies. More tangible than 95% of Healthcare companies in United States.
- Tangible Assets Ratio: Of every $100 the company owns, $100 is in tangible assets such as plants, cash, stock and receivables; the rest is goodwill and other intangibles. More tangible than 94% of Healthcare companies in United States.
Cash quality
Profit Cash Ratio
—Loss-making or profit too small
Over the last 3 years profit was a loss or under 2% of sales, so cash per 100 of profit is not meaningful.
Self-Funding Ratio
-11.8×Over the last 3 years operating cash was negative while the company kept spending on investment (capex).
Lower than 53% of Healthcare companies in United States.
Cash Locked Ratio
$29For every $100 of sales, $29 is tied up in day-to-day operations (money owed by customers + stock − money owed to suppliers), against $48 tied up three years earlier.
More money tied up than 63% of Healthcare companies in United States.
Growth quality
Steadiness Ratio
0/3 · 0/3Sales and profit both fell in each of the last 3 years.
Less steady than 96% of Healthcare companies in United States.
Growth Efficiency Ratio
—Sales fell 25%
Sales fell 25% in 3 years, so extra profit per extra sales cannot be measured.
Asset Productivity Ratio
-25% / -29%In 3 years sales changed by -25% while total assets changed by -29%. Both moved at about the same pace.
Balance-sheet strength
Debt Due Cover Ratio
-23.6×Operating cash was negative last year, while some debt falls due within a year.
Lower than 59% of Healthcare companies in United States.
Cash Cushion Ratio
+58%Cash, after subtracting all debt, equals 58% of its market value (net cash).
Higher than 80% of Healthcare companies in United States.
Tangible Assets Ratio
100%Of every $100 the company owns, $100 is in tangible assets such as plants, cash, stock and receivables; the rest is goodwill and other intangibles.
More tangible than 94% of Healthcare companies in United States.
Tangible Net Worth Ratio
100%Of every $100 of net worth, $100 is tangible; the rest is goodwill and other intangibles, often from buying other companies.
More tangible than 95% of Healthcare companies in United States.
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (12)
MaxCyte, Inc. made a loss over the last year. MaxCyte, Inc. owes $0.14 for every $1 it owns. MaxCyte, Inc. made a loss in each of the last two years.
Compared with Healthcare companies in United States · latest annual results Dec 2025.
P/E ratio
LossMaxCyte, Inc. made a loss over the last year, so its P/E ratio is not meaningful.
P/B ratio
0.93The share price is 0.93 times MaxCyte, Inc.'s book value per share, lower than 80% of Healthcare companies in United States.
Market cap
$148 MThe total market value of all of MaxCyte, Inc.'s shares at today's price (share price × number of shares), smaller than 61% of Healthcare companies in United States. PosiCap size class: Mini Cap.
Net worth (book value)
$159 MWhat MaxCyte, Inc. would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (30 Jun 2026).
Book value per share
$1.54Net worth divided by the number of shares. The share price of $1.43 is 0.9 times this, which is the P/B above.
Return on equity (ROE)
-20.4%MaxCyte, Inc. lost 20.4% of its shareholders' money over the last year, higher than 65% of Healthcare companies in United States.
Owes vs Owns
0.14×MaxCyte, Inc. owes $0.14 for every $1 it owns (low), lower than 81% of Healthcare companies in United States.
Dividend yield
NoneMaxCyte, Inc. does not currently pay a dividend.
Revenue growth
-15%Revenue fell 15% in the year to Dec 2025, and shrank 9% a year on average over 3 years.
Profit growth
LossMaxCyte, Inc. made a loss in each of the last two years.
Profit margin
-135.1%MaxCyte, Inc. lost $135 for every $100 of revenue.
Cash vs debt
Net cashMaxCyte, Inc. held $85 M more cash than debt (net cash) at Dec 2025.
Questions
How is P/B calculated on PositoAI?
P/B is market cap divided by net worth from the latest balance sheet. For MaxCyte, Inc.: $148 M ÷ $159 M (30 Jun 2026) = 0.9.
What is MaxCyte, Inc.'s return on equity?
MaxCyte, Inc. lost 20.4% of its shareholders' money over the last year, higher than 65% of Healthcare companies in United States.
How much does MaxCyte, Inc. owe compared with what it owns?
MaxCyte, Inc. owes $0.14 for every $1 it owns (low), lower than 81% of Healthcare companies in United States.
Does MaxCyte, Inc. pay a dividend?
No. MaxCyte, Inc. does not currently pay a dividend.
Is MaxCyte, Inc.'s revenue growing?
Revenue fell 15% in the year to Dec 2025, and shrank 9% a year on average over 3 years.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.